Roth reportedly sees big upside for Can-Fite Bio

Roth is reportedly out lifting its price target on Can-Fite BioPharma (CANF) on the heels of positive data from a Phase 2b RA trial.

Target is now $28 (from $15), representing upside of 282% from Friday's close.

See: CANF rallies on RA data

CANF +20% premarket

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs